ArticleBiology direct2026
Plasma metabolomic profiling identifies a metabolic signature for non-muscle-invasive bladder cancer independent of hematuria.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of bladder cancer cases and, despite a generally favorable prognosis, requires lifelong cystoscopic surveillance, resulting in substantial clinical burden. Non-invasive biomarkers with metabolic and translational relevance are needed to improve disease detection and patient stratification. Plasma represents a stable systemic matrix that captures tumor-associated metabolic alterations while minimizing pre-analytical variability.
resultsTargeted metabolomic profiling of 630 metabolites and 252 metabolic indicators was performed in plasma samples from 249 individuals, including 51 patients with NMIBC and 198 control individuals. Integrated univariate and multivariate analyses were used to identify discriminant metabolites, assess pathway-level perturbations, and develop diagnostic models. Model robustness was evaluated with respect to hematuria status. A total of 29 metabolites and 17 metabolic indicators were significantly altered in NMIBC. The dominant metabolic signature involved lipid and bile acid metabolism, characterized by reduced conjugated bile acids and increased lysophosphatidylcholines and polyunsaturated fatty acid species. Pathway enrichment analysis indicated perturbations in bile acid biosynthesis, PUFA turnover, glutathione metabolism, and glycolytic pathways. A diagnostic model based on 11 metabolites achieved high accuracy (AUC = 0.92 in the training set and 0.88 in the test set). Hematuria status did not affect clustering or model performance.
conclusionsPlasma metabolomic profiling identifies a systemic metabolic signature associated with lipid and bile acid dysregulation in NMIBC and supports the development of clinically applicable, non-invasive plasma-based approaches for bladder cancer detection and patient stratification. Further validation in independent and longitudinal cohorts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.